Prime management looks forward to participating in a number of investor conferences throughout September. Live audio webcasts of each presentation will be available under “Events & Presentations” in the News & Events section of our website. Full details here. https://lnkd.in/gWB7kJC4
Prime Medicine, Inc.
Biotechnology Research
Cambridge, Massachusetts 17,300 followers
Delivering on the promise of Prime Editing
Über uns
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.
- Website
-
http://www.primemedicine.com
External link for Prime Medicine, Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- Cambridge, Massachusetts
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2019
- Spezialitäten
- Gene Editing
Standorte
-
Primäre
Wegbeschreibung erhalten
60 First St
Cambridge, Massachusetts 02141, US
Employees at Prime Medicine, Inc.
Aktualisierungen
-
We are looking forward to the #CHIBioprocessingSummit in Boston next week! Scientists Weiyi Li, Joseph Elich and Amanda Jay will be presenting, and leadership team members Ann Lee and Niamh Alix will be moderating panel discussions. Learn more about this year's summit here. https://lnkd.in/eDaJ__r
-
We are excited to announce the appointment of Mohammed Asmal as Chief Medical Officer! As Head of Clinical since 2022, he has played an essential role in leading clinical development strategy across our portfolio.
-
-
The potential of gene editing therapies is vast, and Prime Editing is at the "clinical frontier" of advancement as the field continues to evolve. The Economist's Natasha Loder shares insight on the potential of gene editing to reshape the standard of care for numerous diseases. Read more below.
-
A message about employment scams: Please note that Prime Medicine does not reach out to job applicants via social media and messaging platforms such as Facebook, Instagram, Skype, or WhatsApp. The only email domain we use for official business is @primemedicine.com, and our employees will never use alternate email addresses to contact candidates. Our team members will never request personal financial information or identification details, including bank account, social security, or driver’s license numbers. Additionally, we will not charge any fees, mail checks for equipment, nor ask you to make purchases as part of our hiring process.
-
Prime recently celebrated #PrideMonth with vibrant rainbow leis, flags, pins and delicious cookies. We enjoyed an afternoon filled with laughter as we celebrated love and diversity. We’re keeping the celebration going with an internal Prime Pride Anthems playlist featuring our favorite LGBTQIA+ artists and songs that embody the spirit of this month. Happy Pride, everyone! 🏳️🌈
-
-
Listen below as CEO Keith Gottesdiener shares insight into his career trajectory, from a practicing physician to chief executive officer, on the latest episode of SSI Strategy’s The Emerging Biotech Leader podcast!
In the latest episode of the Emerging Biotech Leader podcast, our hosts Kimberly F. Kushner & Ramin Farhood sit down with Keith Gottesdiener, President and CEO of Prime Medicine. Keith shares his unique career journey that took him from treating patients as a physician to leading cutting-edge biotech companies. Hear his first-hand perspective on: 💼 Transitioning from academia to the corporate world 💡 Embracing an entrepreneurial mindset as CEO 👥 Building high-performing teams aligned with the company vision Listen now for an inside look at redefining career roles and steering ambitious biotech ventures towards success. https://lnkd.in/dZaiBUwF
-
-
We are excited to see new research from Prime co-founder David R. Liu's lab in Nature Portfolio Biomedical Engineering, detailing work on the development of the eePASSIGE system, which uses evolved and engineered recombinases and Prime Editing to integrate large gene-sized #DNA cargoes into the mammalian genome in an efficient, precise and targeted manner. This proprietary approach further increases the versatility of Prime Editing and broadens the range of permanent genomic edits that Prime Editing can make to treat disease. Congratulations to the team on this important publication!
Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing - Nature Biomedical Engineering
nature.com
-
We are pleased to share members of management will participate in healthcare conferences hosted by Jefferies and Goldman Sachs in June. Details below. https://lnkd.in/gU5amPjc
-
-
Prime CFO Allan Reine will participate in a fireside chat at an H.C. Wainwright conference this month. Details below. https://lnkd.in/e3VCszF2
-